Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 6 of 151

  1. 64007957MMY1003

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  2. 64007957MMY3001

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  3. 64042056ALZ2001

    Janssen-Cilag International N.V.

    Preclinical Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  4. 64407564MMY1001

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  5. 64407564MMY2006

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 2 small molecule active

    1 trial

  6. 67-22 PREcoopERA

    Partner Therapeutics Limited

    ER-positive/HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  7. 68284528MMY2012

    Janssen-Cilag International N.V.

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  8. 68GA-FAPI-46

    Disc Medicine

    Graves' Orbitopathy

    phase 2 small molecule active

    1 trial

  9. 68Ga-DOTATATE and 68Ga-FAPI

    The First People's Hospital of Lianyungang

    Tumor Positron-Emission Tomography

    phase 2 small molecule completed

    1 trial

  10. 68Ga-Dotatoc

    Disc Medicine

    nasopharyngeal carcinoma

    phase 2 small molecule active

    1 trial

  11. 68Ga-FAP-CHX

    The First People's Hospital of Lianyungang

    Tumor

    phase 2 small molecule active

    1 trial

  12. 68Ga-FAPI-46

    Istituto Gentili S.r.l.

    oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT

    phase 2 small molecule active

    1 trial

  13. 68Ga-FAPI-46

    The George Institute

    Triple-negative breast cancer (TNBC) patients at high risk of relapse

    phase 2 small molecule active

    1 trial

  14. 68Ga-FAPI-46

    The George Institute

    Non-metastatic Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. 68Ga-FAPI-46, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis, axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  16. 68Ga-G21

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  17. 68Ga-NODAGA-SNA006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 2 small molecule active

    1 trial

  18. 68Ga-NY104 PET/CT

    Peking University Third Hospital

    Clear Cell Renal Cell Carcinoma

    phase 2 other active

    1 trial

  19. 68Ga-NY104 PET/CT

    The First People's Hospital of Lianyungang

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. 68Ga-Pentixafor

    Peking University Third Hospital

    Cushing s Syndrome

    phase 2 small molecule active

    1 trial

  21. 6QC-ICG, Placebo for 6QC-ICG

    Disc Medicine

    Breast cancer

    phase 2 small molecule active

    1 trial

  22. 6R BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Kidney Disease

    phase 2 small molecule completed

    1 trial

  23. 6R-BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Isolated Systolic Hypertension

    phase 2 small molecule terminated

    1 trial

  24. 6R-BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  25. 6R-BH4 (sapropterin dihydrochloride)

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypertension

    phase 2 small molecule completed

    1 trial

  26. 70 mL red beetroot juice

    United Therapeutics Europe Ltd

    Overweight

    phase 2 other active

    1 trial

  27. 747-213

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  28. 75 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  29. 75mg SHP647 (PF-00547659)

    Takeda

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  30. 77242113UCO2001

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  31. 78934804CRD2001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  32. 78934804UCO2001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  33. 80 mg DR-6MP

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  34. 80202135CDP3001

    Janssen-Cilag International N.V.

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  35. 80202135IIM2001

    Janssen-Cilag International N.V.

    Active Idiopathic Inflammatory Myopathies (IIM)

    phase 2 small molecule active

    1 trial

  36. 81201887MDG3002

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  37. 817P203

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    1 trial

  38. 851B

    Takeda

    Papillomavirus Infections

    phase 2 small molecule terminated

    2 trials

  39. 88545223PSA2001

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  40. 8951-CL-0103

    Astellas Pharma GmbH

    Advanced cancer of the stomach or the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  41. 8951-CL-5201

    Astellas Pharma GmbH

    First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.

    phase 2 small molecule active

    1 trial

  42. 89Zr-Bevacizumab

    Disc Medicine

    NF2-related schwannomatosis

    phase 2 small molecule active

    1 trial

  43. 89Zr-Girentuximab

    Telix Innovations

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  44. 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors

    Telix Innovations

    Cervical Cancer

    phase 2 other terminated

    1 trial

  45. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  46. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Salivary Gland Carcinoma

    phase 2 small molecule terminated

    1 trial

  47. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Cancer

    phase 2 small molecule active

    1 trial

  48. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Pancreatic Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.